Read: Mastering Private Equity by Claudia Zeisberger
What happens when the private equity boom meets a world of higher rates and lower liquidity? INSEAD Professor Claudia Zeisberger returns with a rewritten edition of Mastering Private Equity for a new ...
10 Okt 202525min
Money and Me: The ACE Strategy — Gold, Tech and Emerging Markets
Gold surges past US$4,000. Tech valuations swing. Emerging markets rise as supply chains shift east. Are KGI’s “ACE” pillars - Alternatives, Credit, and Elite Stocks - still winning in 2025? Bryan Low...
10 Okt 202514min
Market View: The Debasement Trade and Hong Kong’s $14B Bet
Gold surges, Hong Kong banks tumble, and Uniqlo hits another record - what’s really driving markets this week? HSBC’s massive Hang Seng buyout shocks investors, while Wall Street buzzes over the “deba...
10 Okt 202524min
Money and Me: Beyond Macro Fears – Finding Value in Asian Equities
Can Asia’s economic resilience and the AI revolution shield its markets from U.S. political turbulence? Morningstar’s Kai Wang joins Michelle Martin to break down where the real long-term value lies i...
8 Okt 202518min
Market View: Gold Breaks $4,000 — What It Signals for Investors
Gold smashes through the $4,000 mark for the first time ever, igniting debate over whether this is a 1970s-style inflation hedge moment or a sign of fear overtaking fundamentals. Michelle Martin break...
8 Okt 202514min
Money and Me: SSB investors - what's next?
What would you do if $129,600 landed back in your account overnight? Hosted by Michelle Martin, this episode dives into the maturity of Singapore’s first-ever 10-year Savings Bond and what investors m...
7 Okt 202524min
Market View: Integrating AI & Software in Style
OpenAI doubles down on the AI arms race - first Nvidia, now AMD. But what does a trillion-dollar chip war mean for investors? Hosted by Michelle Martin, this episode breaks down OpenAI’s new stake in ...
7 Okt 202515min
Influence: The Vaccine Visionary Who Puts Lives Before Profit
Meet Mr Hyun Soo Kim, Founder and CEO of Sun Biotech, who’s spent 25 years developing vaccines for diseases big pharma overlooks. From pioneering the first WHO-prequalified vaccine from China to launc...
6 Okt 202516min
